Listen
Reason for request
Request for inclusion on the list of medicines refundable by National Health Insurance and approved for hospital use in the extension of indication to the “treatment of adults with inflammation of the posterior segment of the eye presenting as non-infectious uveitis”.
-
Clinical Benefit
| Substantial |
The actual benefit of OZURDEX 700 micrograms, intravitreal implant in applicator, is substantial in this indication. |
Clinical Added Value
| moderate |
OZURDEX 700 μg, intravitreal implant in applicator, provides a moderate improvement in actual benefit (IAB III) in the management of adult patients with inflammation of the posterior segment of the eye presenting as non-infectious uveitis. |
English version
Contact Us
Évaluation des médicaments
